[Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: a review]

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in many solid tumors.
• EGFR inhibitors show promise in cancer treatment but frequently cause cutaneous toxicities, such as severe rash.
• The exact mechanisms behind these skin side effects are not fully understood.

Purpose of the Study:

• To review the clinical presentations of cutaneous toxicities induced by EGFR inhibitors.
• To summarize current management strategies for these side effects.
• To explore the potential of rash severity as a predictive marker for anti-tumoral response.

Main Methods:

• Literature review of clinical studies on EGFR inhibitors and their dermatological side effects.
• Analysis of reported correlations between rash severity and treatment efficacy.
• Synthesis of current clinical guidelines for managing EGFR inhibitor-induced rash.

Main Results:

• Cutaneous rash is a common and often distressing side effect of EGFR inhibitor therapy.
• Some studies suggest a correlation between rash severity and positive tumoral response.
• Effective management strategies exist to mitigate the impact of these toxicities.

Conclusions:

• EGFR inhibitors are vital cancer therapeutics, but managing their associated skin toxicities is crucial.
• Further research is needed to confirm the rash as a reliable biomarker for treatment efficacy.
• Optimizing management of cutaneous toxicities can improve patient adherence and outcomes.